Amidst a backdrop of political shifts and economic recalibrations, the French market has shown resilience with the CAC 40 Index climbing significantly. This positive momentum in France’s market landscape sets an intriguing stage for discussing growth companies with high insider ownership, which often signals strong confidence in a company's future from those who know it best. Top 10 Growth Companies With High Insider Ownership In France Name Insider Ownership Earnings Growth VusionGroup (ENXTPA:VU) 13.5% 25.2% Groupe OKwind Société anonyme (ENXTPA:ALOKW) 24.8% 30.8% Adocia (ENXTPA:ADOC) 11.9% 63% Icape Holding (ENXTPA:ALICA) 30.2% 26.2% Arcure (ENXTPA:ALCUR) 21.4% 42.4% La Française de l'Energie (ENXTPA:FDE) 20.1% 31.9% S.M.A.I.O (ENXTPA:ALSMA) 17.3% 35.2% Munic (ENXTPA:ALMUN) 29.4% 149.2% MedinCell (ENXTPA:MEDCL) 16.4% 70.4% OSE Immunotherapeutics (ENXTPA:OSE) 25.6% 5.9% Click here to see the full list of 21 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener. We'll examine a selection from our screener results. Exclusive Networks Simply Wall St Growth Rating: ★★★★☆☆ Overview: Exclusive Networks SA is a global cybersecurity specialist focusing on digital infrastructure, with a market capitalization of approximately €2.09 billion. Operations: The company's revenue is primarily generated from three geographical segments: APAC (€420 million), EMEA (€4.04 billion), and the Americas (€689 million). Insider Ownership: 13.2% Revenue Growth Forecast: 14.4% p.a. Exclusive Networks, a French growth company with high insider ownership, recently appointed KPMG as its new auditor. Despite a slight decline in Q1 2024 revenue to €393 million from €399 million the previous year, the company maintains an optimistic outlook with expected revenue growth of 10-12% for FY 2024. Exclusive Networks has demonstrated robust earnings growth of 19.4% over the past year and anticipates significant profit increases at an annual rate of 28.4%, outpacing the French market's forecasted earnings growth. Get an in-depth perspective on Exclusive Networks' performance by reading our analyst estimates report here. Our expertly prepared valuation report Exclusive Networks implies its share price may be too high. ENXTPA:EXN Ownership Breakdown as at Jul 2024 Lectra Simply Wall St Growth Rating: ★★★★☆☆ Overview: Lectra SA offers industrial intelligence solutions across the fashion, automotive, and furniture sectors in various global regions including Northern Europe, Southern Europe, the Americas, and Asia Pacific, with a market capitalization of approximately €1.11 billion. Operations: Revenue for the company across its key geographical segments includes €170.33 million from the Americas and €110.28 million from the Asia Pacific region. Insider Ownership: 19.6% Revenue Growth Forecast: 11.3% p.a. Lectra, a French growth company with high insider ownership, is trading at 33.4% below its estimated fair value, highlighting potential undervaluation. With earnings forecasted to grow at 28.6% annually over the next three years—surpassing the French market's expected 10.9%—and revenue projected to increase by 11.3% annually, Lectra shows promising financial trends despite a slight dip in net income and EPS in Q1 2024 compared to the previous year. Delve into the full analysis future growth report here for a deeper understanding of Lectra. Upon reviewing our latest valuation report, Lectra's share price might be too pessimistic. ENXTPA:LSS Earnings and Revenue Growth as at Jul 2024 MedinCell Simply Wall St Growth Rating: ★★★★★☆ Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €431.26 million. Operations: The company generates its revenue primarily from the pharmaceuticals segment, totaling €11.95 million. Insider Ownership: 16.4% Revenue Growth Forecast: 43.8% p.a. MedinCell S.A., a French growth company with substantial insider ownership, is currently trading 4.2% below its estimated fair value, suggesting potential undervaluation. Despite experiencing a volatile share price in recent months and shareholder dilution over the past year, MedinCell's financial outlook appears robust with earnings expected to grow by 70.38% annually. Revenue growth is also projected to outpace the market significantly at 43.8% per year compared to the French market's 5.7%. However, recent clinical trial setbacks could pose challenges to its growth trajectory. Dive into the specifics of MedinCell here with our thorough growth forecast report. The analysis detailed in our MedinCell valuation report hints at an inflated share price compared to its estimated value. ENXTPA:MEDCL Earnings and Revenue Growth as at Jul 2024 Key Takeaways Navigate through the entire inventory of 21 Fast Growing Euronext Paris Companies With High Insider Ownership here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Looking For Alternative Opportunities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ENXTPA:EXNENXTPA:LSS and ENXTPA:MEDCL. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Euronext Paris Showcases Three Growth Companies With High Insider Ownership
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...